Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Here is a couple links.
http://ih.advfn.com/p.php?pid=nmona&article=50557167
Through the offering, which commenced on October 15, 2011, the Company received $5,000,000 in proceeds and issued 5% Convertible Senior Secured Promissory Notes that are convertible into approximately 5,000,000 shares of common stock at a price of $1.00 per share. Participating investors also received contingent warrants to purchase the Company's common stock. More details regarding the private placement, including the terms of the warrants, are disclosed in the Company's SEC filings.
http://ih.advfn.com/p.php?pid=nmona&article=48336961
From the commencement of the offering on October 30, 2010, through June 30, 2011, the Company sold approximately 6,545,000 shares of common stock at a price of $1.00 per share and received proceeds of approximately $6,417,000, net of $128,000 in offering costs. Participating investors also received warrants to purchase the Company's common stock. Through June 30, 2011, the Company issued a total of 3,272,500 warrants. More details regarding the private placement, including the terms of the warrants, are disclosed in the Company's SEC filings.
Also 3Q for 2011-
http://ih.advfn.com/p.php?pid=nmona&article=49944441
ADXS- I am curious as to why nothing has been followed up with the Numoda deal. http://www.numoda.com/pages/media.html
Anyways Mr. 12 mil needs to finish up and let this thing breath again. I think they have a ways to go with the re-sell though. Since the announcement of the re-sell, ADXS has only had 6-7 mil in trading volume.
I believe it was 5 mil at a dollar. I think they also sold 6.5 mil, at a dollar, from 2010 - 2011. I will have to pull that back up when I get back in front of my computer.
That was what I was thinking as well. Interesting that a/s was reduced though, typically those numbers are never reduced.
Was not able to pull up anything further, however, I did error on my previous post. The first of two presentations actually starts tomorrow. The second is later this week. I think questions will be answered on the 28th, when the full year 2011 numbers come out.
MDXG- been on the move the past few trading days. They had a couple of presentations at the end of January and have there full year report coming up end of month. Going to do some digging and see if I can find anything more.
Congrats Stills!
I hear ya. Load up time is now and then once this goes to the moon of the moon, you can buy out that web- site! Lol
I agree with that. Andre Reed is another one that comes to mind. Canton most not like WRs.
I am ready for it. Going to need a background with some strobe lights for that one.
He was a good player for a few years. Tim brown and Chris Carter should have made it. Two of the best WRs.
To da moon! Good stuff.
This thing has been trading oddly the last two days. I think Malc brought this up yesterday. This thing is boxed in for no reason. It gets whacked as soon as it starts to move up. What I find weird is the post Stills found on yahoo about a new finance deal, yet nothing from the co. released. Makes me wonder if this recent trading is in connection with that.
The two things I can think of is they have FDA approval. I believe the O/S is close to half of what VRSEF is. VRSEF is going to be in a holding pattern until FDA news comes or actual sales begin.
Thanks for the dig up. I was wondering if more shares were being issued or what was going on. Hopefully there is not many left to be sold.
That blows my mind. At least I got my shares though
Here is the link for the phase 1 trials.
http://www.drugs.com/clinical_trials/fifteen-percent-adxs11-001-treated-cervix-cancer-patients-still-alive-three-years-after-initial-8747.html
The video presentation Malc posted earlier had some good info in it. More results to come in through Feb.
I posted the PR from phase 1 about 30 mins ago. They used 2 doses in phase 1 to check the safety. Higher dosing in phase 2.
3.8 to 6.2 months is the expected survival time for patients that enrolled in phase 1 trials. I'm sure it would the same or similar for phase 2.
Here is PR from Phase I studies. Gives a little bit of information on the survial rate of the patients enrolled.
http://www.drugs.com/clinical_trials/fifteen-percent-adxs11-001-treated-cervix-cancer-patients-still-alive-three-years-after-initial-8747.html
Updated Advaxis Phase I Survival Data Indicates Continued Long-Term Immune Protection
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Dec 28, 2009 - The Phase I trial of ADXS11-001, the lead vaccine candidate of Advaxis, Inc., (OTCBB: ADXS), the company that pioneered the live, attenuated Listeria monocytogenes (Lm) vaccine, has shown thirty-six (36) month survival in two (2) of the thirteen (13) evaluable patients treated with Advaxis' therapeutic cancer vaccine, indicating the possibility of persistent immune protection, from only a two (2) dose initial regimen.
The patients had participated in the first human trial of a live Listeria vaccine for the treatment of advanced, recurrent, metastatic cervix cancer in women who have failed prior cytotoxic treatment. Advaxis is tracking the survival of these patients at three (3) month intervals.
These mortality figures substantially exceed the median survival rate established by the National Cancer Institute's Gynecologic Oncology Group (GOG), which varies between 3.8 and 6.2 months in studies of patients who have failed prior cytotoxic treatment including chemotherapy with various agents (GOG Protocol #127).
Earlier this year, Advaxis published in the medical journal Vaccine the fact that four (4) of thirteen (13) evaluable patients, treated with ADXS11-001, experienced tumor reductions, two (2) patients had lesions disappear and fifty-three percent (53%) survived more than one (1) year; thus, posting a median survival rate of 347 days. Although this trial was designed to assess safety – not efficacy or survival – two (2) of the thirteen (13) patients or fifteen percent (15%) evaluable for efficacy are still alive, at over 1,000 days post-dosing with the study drug, as of December 10, 2009. One patient, who had been the longest surviving patient, passed away since the previous 90-day update.
I would think the market would catch on but who knows. I guess we will find out tomorrow. Either way, with more results coming through, I wouldn't imagine it going unnoticed for very long.
Like the looks of that. AD line not so hot. I would imagine their will be some positive volume to change that. VRSEF needs to take notice. Saw it crossed over the wrong way the other day. Not to worried about that though.
I was impressed by the presentation Malc put up. I can see it does have to be somewhat later stages, but not at the current testing stage. I would love to see data on not such a late stage. My @ss needs to get out of bed tomorrow before the bell. Lol
Thanks for the video to. The numbers and info was great. To partner up with a big pharma for phase 3 will be huge. 75% elimination/reduction in animals, I know not human, but still impressive. This should easily get fast tracked if the upcoming results keep pace.
ADXS- have not followed this co. but those numbers are impressive to me. To have 3 patients with complete elimination of tumors that late in stage is amazing and another 6 showing reductions. Is the plan for this drug to be issued only in these late stages or can it be admin. before?
Agree with that. Figured it would be at least .75 not dropping to .65. Gives us more time to pick some up at great prices.
VRSEF
I'm ready to see the published results. If they are going to release them prior to this weekends conference, tomorrow could be the day.
Added link to my previous post.
VRSEF
New article out on there web-site. Nothing really new in the article but a good read.
Edit- http://www.canhealth.com/tfdnews0458.html
Amazon does have there own VOD service. You can either purchase the movie or stream it for a couple of dollars. IFC also has a VOD service. This is going to be a direct competitor.
http://www.ifcfilms.com/
There are so many different VOD serives out there. Netflix also has a huge gallery of Independent films. Netflix does have The Wild and Wonderul Whites of West Virginia. Did not watch it but remember seeing it a couple of weeks ago searching for movies.
If HHSE does not over extend, on cash to get this going, it could be a nice little revenue stream. I would not expect it to be huge revs but would generate some cash. Also, MA nailed a good point with this service. This will get there name out a little more and hopefully build other relationships.
MDXG- the share increase is a bit of a concern but it is much needed to get production going. Even maxed out, I think they are in good shape. If they hit there goals, a lot of those shares won't be issued. Not sure if the A/S increase is a sign of things to come though. Hopefully in march, when the year end report is due, those questions will be answered. A bit of a black eye was dealt today with the news. Not sure how to take that.
VRSEF- those placements may have something to do with it. It could be a mix of that and other short term traders. I also think the lack of MMs could be the issue as well.
.40 and .50 warrants.
http://verisante.com/news/48/skin-cancer-detection-company-completes-5-million-private-placement-industrial-space-expanded-analysis-of-clinical-trial-data/
They also did this in Feb. 2011
http://verisante.com/news/41/verisante-completes-private-placement-announces-attendance-at-the-american-academy-of-dermatology-meeting/
Very nice. Now if the MMs would stop walking the ask down, we could keep this uptrend going.
Its looking good. VRSEF needs to show up to the party now!
Should have also noted that my numbers include the 21 mil, that they are non-dilutive, from the 3Q. If you take those out, they are right around the 85 that you stated.
I am not the greatest at calculating the fully diluted OS and why I originally wanted to wait for the fins to buy in. With the new 8-K, there is a total of 7.5 mil that can be converted. The original 5 mil and 2.5 mil in contingent warrants. I believe there would be around 103-105 mil, if fully diluted.
Additionally, the Company issued to each lender a warrant (the “ First Contingent Warrant ”) to purchase that number of shares of Common Stock equal to 25% of the shares of Common Stock that would be issuable upon conversion of the principal of such lender’s Note, at an exercise price of .01 per share, provided that such First Contingent Warrant shall only be exercisable if the Company’s gross revenues, as reported in the Company’s audited financial statements for the year ended December 31, 2011, do not equal or exceed $11,500,000. The Company also issued to each lender an additional warrant (the “ Second Contingent Warrant ”) to purchase that number of shares of Common Stock equal to 25% of the shares of Common Stock that would be issuable upon conversion of the principal of such lender’s Note at an exercise price of .01 per share, provided that such Second Contingent Warrant shall only be exercisable if the Company’s gross revenues, as reported in the Company’s audited financial statements for the year ended December 31, 2012, do not equal or exceed $31,150,000, and further provided that such Second Contingent Warrant shall be null and void in the event that, between the date of issuance of the Company’s audited financial statements for the year ended December 31, 2011, (the “ First Measurement Date ”) and the date of issuance of such audited financial statements for the year ended December 31, 2012, (the “ Second Measurement Date ”), the closing trading price of the Common Stock is at least $1.75 for ten or more consecutive trading days. The First Contingent Warrant and the Second Contingent Warrant are hereinafter referred to, collectively, as the “ Contingent Warrants ”. The maximum number of shares of Common Stock issuable upon exercise of the Contingent Warrants is 2,500,000 shares. The Contingent Warrants have a term of five years from the date of issuance. The shares of Common Stock issuable upon exercise of the Contingent Warrants do not carry registration rights. The Contingent Warrants may be exercised on a “cashless” basis.
http://ih.advfn.com/p.php?pid=nmona&article=50603707
BOD and Medical Advisory Board is no joke. They have a great list.
http://www.mimedx.com/about-us/board-of-directors/
They are just begining to transform from R&D to production. 2011 was the first year they really started production. They are expanding there facilities in order to get production going.
http://www.bizjournals.com/atlanta/print-edition/2011/03/18/mimedx-group-plans-to-expand-its.html
EpiFix will be covered by Medicare. Huge news. More patients will have access to there products. Hopefully they can get there other products qualifed as well.
http://ih.advfn.com/p.php?pid=nmona&article=50310044
Also received Seal of Approval from APMA, for EpiFix.
http://ih.advfn.com/p.php?pid=nmona&article=49275649
Has partnered with Affirmative Solutions who is supplier for VA and DOD.
http://ih.advfn.com/p.php?pid=nmona&article=49252247
IMO they have great connections to get there products out. They seem to be well known and not some small company trying to make a name for themselves and be noticed. They still have products waiting to be approved for sale. Have a few out already, that are producing revs. They still have some work to do in there transitional period from R&D to production, but they are on there way.
This is one thing that I do not like. They have quite a few options out and need to up the authorized shares by 10 mil in order to fulfil those options.
The Articles currently authorize the issuance of up to 105,000,000 shares of capital stock of which 100,000,000 shares are designated as common stock ($.001 par value) and 5,000,000 shares are designated as preferred stock ($.001 par value). As of the close of business on November 10, 2011, 74,256,895 shares of common stock were outstanding. In addition, as of the close of business on November 10, 2011, the Company had 13,416,250 shares of common stock subject to outstanding stock options, 140,000 shares reserved for issuance pursuant to future grants under the Company’s current stock incentive plans, and 12,091,899 shares of common stock subject to outstanding warrants. No preferred stock has been issued or is outstanding. The proposed amendment will not increase or otherwise affect the Company’s authorized preferred stock
Now those numbers do not include the current filing that you posted. Now they will have 115 mil authorized, which is not bad. Most of there funding have been through PIPEs, so they are going to have quite a few converts throughout this year. They expected to be cash flow positive towards the end of 2011. They missed that mark with the current filing. They could see that in 2012. EOY report not due until March, so it will be a while to see those numbers.
http://ih.advfn.com/p.php?pid=nmona&article=50166209#C25165DEF14A_HTM_C25165106
You beat me to it. Looking good with CE approval. Dr. James Andrews looks to be a big supporter for CollaFix. FDA approval will be huge for this product.
I am sorry to be reading this. Hope all is well.